Previous 10 | Next 10 |
Gainers: Veru (VERU) +196%. Hoth Therapeutics (HOTH) +126%. Altamira Therapeutics (CYTO) +54%. Iveda Solutions (IVDA) +37%. VNET Group (VNET) +30%. SailPoint Technologies Holdings (SAIL) +29%. Castor Maritime (CTRM) +25%. Datto Holding (MSP) +21%. Axcella Health (AXLA) +16%. TScan Therapeutic...
Shares of microcap Phio Pharmaceuticals (NASDAQ:PHIO) have fallen 20.9% on Monday, after more than doubling in value on Friday following the announcement of what the company deemed to be positive preclinical data for its RNAi compound candidate PH-894. Phio on Friday said data from in vivo st...
NEW YORK, April 11, 2022 (GLOBE NEWSWIRE) -- Wall Street Reporter, the trusted name in financial news since 1843, has published reports on the latest comments and insights from CEO’s of: Nova Mentis Life Sciences (OTC: NMLSF) (CSE: NOVA), Phio Pharmaceuticals (NASDAQ: PHIO), Veru Inc...
Are These Penny Stocks on Your List Right Now? There are a lot of different ways to make money with penny stocks, but knowing what they are and how to trade is crucial. When you purchase penny stocks , you are likely to see very large price swings in a short time frame. For exam...
Phio Pharmaceuticals Presents Positive New Data on PH-894 Demonstrating Antitumor Efficacy in Model of PD-1 Refractory Disease at the AACR Annual Meeting 2022 PR Newswire MARLBOROUGH, Mass. , April 8, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (NASDA...
Phio Pharmaceuticals press release (NASDAQ:PHIO): FY GAAP EPS of -$1.04 beats by $0.07. At December 31, 2021, the Company had cash of $24.1 million as compared with $14.2 million at December 31, 2020. The Company expects its current cash will be sufficient to fund currently planned operations...
Phio Pharmaceuticals Reports 2021 Year End Financial Results and Provides Business Update PR Newswire Company transitioning into a clinical stage company with start of the first clinical study for lead program, PH-762. MARLBOROUGH, Mass. , March 22, 2022 ...
Phio Pharmaceuticals Announces Upcoming Presentation of PH-894 Data at the AACR Annual Meeting 2022 PR Newswire MARLBOROUGH, Mass. , March 8, 2022 /PRNewswire/ -- Phio Pharmaceuticals Corp. (Nasdaq: PHIO), a clinical stage biotechnology company developing th...
Phio Pharmaceuticals Initiates In Vivo Studies of INTASYL Based Antivirals Against SARS-CoV-2 Advancement of additional studies is based on positive results from in vitro studies and the ongoing COVID-19 pandemic PR Newswire MARLBOROUGH, Mass. , Feb. 22, 2022 ...
InvestorPlace - Stock Market News, Stock Advice & Trading Tips We’re seeing major movement from some hot penny stocks today and are diving into what has them on the rise! Source: John Brueske/Shutterstock.com Before we get too far in. Just remember that penny stocks are ...
News, Short Squeeze, Breakout and More Instantly...
Phio Pharmaceuticals Corp. Company Name:
PHIO Stock Symbol:
NASDAQ Market:
Phio Pharmaceuticals Corp. Website:
Marlborough, Massachusetts--(Newsfile Corp. - July 12, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO) (the "Company"), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells...
Five sites across the U.S. are now participating in the Phase 1b study Marlborough, Massachusetts--(Newsfile Corp. - July 8, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to ...
Marlborough, Massachusetts--(Newsfile Corp. - July 5, 2024) - Phio Pharmaceuticals Corp. (NASDAQ: PHIO), a clinical stage biotechnology company whose proprietary INTASYL® siRNA gene silencing technology is designed to make immune cells more effective in killing tumor cells, today announced i...